Primecap Management Co. CA Reduces Holdings in Revvity Inc. $RVTY

Primecap Management Co. CA trimmed its holdings in shares of Revvity Inc. (NYSE:RVTY) by 2.0% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,332,831 shares of the company’s stock after selling 26,810 shares during the quarter. Primecap Management Co. CA’s holdings in Revvity were worth $116,823,000 at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. CYBER HORNET ETFs LLC purchased a new position in shares of Revvity during the 2nd quarter worth $32,000. MUFG Securities EMEA plc purchased a new stake in shares of Revvity in the 2nd quarter worth $34,000. Headlands Technologies LLC bought a new position in Revvity in the 2nd quarter worth $49,000. Smartleaf Asset Management LLC lifted its position in Revvity by 56.8% during the third quarter. Smartleaf Asset Management LLC now owns 690 shares of the company’s stock valued at $58,000 after purchasing an additional 250 shares in the last quarter. Finally, Quent Capital LLC purchased a new position in Revvity during the third quarter valued at $71,000. 86.65% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of analysts have commented on RVTY shares. JPMorgan Chase & Co. upped their price target on Revvity from $100.00 to $105.00 and gave the stock a “neutral” rating in a research report on Tuesday, February 3rd. The Goldman Sachs Group initiated coverage on Revvity in a research note on Tuesday, December 9th. They set a “neutral” rating and a $105.00 price objective for the company. Jefferies Financial Group raised their target price on shares of Revvity from $100.00 to $105.00 and gave the stock a “hold” rating in a research note on Monday, February 2nd. Bank of America downgraded shares of Revvity from a “buy” rating to a “neutral” rating and set a $110.00 price target on the stock. in a report on Monday, December 15th. Finally, Barclays upped their price target on shares of Revvity from $115.00 to $118.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 3rd. Five research analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Revvity currently has an average rating of “Hold” and an average price target of $113.67.

Revvity Stock Performance

NYSE:RVTY opened at $98.97 on Friday. The company has a market cap of $11.06 billion, a price-to-earnings ratio of 47.58, a PEG ratio of 2.07 and a beta of 1.07. Revvity Inc. has a 1 year low of $81.36 and a 1 year high of $120.39. The stock’s 50 day simple moving average is $103.27 and its two-hundred day simple moving average is $96.32. The company has a debt-to-equity ratio of 0.36, a current ratio of 1.68 and a quick ratio of 1.40.

Revvity (NYSE:RVTY) last posted its earnings results on Monday, February 2nd. The company reported $1.70 EPS for the quarter, beating analysts’ consensus estimates of $1.55 by $0.15. Revvity had a return on equity of 7.92% and a net margin of 8.45%.The firm had revenue of $772.06 million during the quarter, compared to the consensus estimate of $759.81 million. During the same period in the prior year, the company earned $1.42 EPS. The company’s quarterly revenue was up 5.9% compared to the same quarter last year. Revvity has set its FY 2026 guidance at 5.350-5.450 EPS. As a group, equities analysts anticipate that Revvity Inc. will post 4.94 earnings per share for the current fiscal year.

Revvity Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, May 8th. Shareholders of record on Friday, April 17th will be paid a $0.07 dividend. This represents a $0.28 dividend on an annualized basis and a dividend yield of 0.3%. The ex-dividend date of this dividend is Friday, April 17th. Revvity’s dividend payout ratio (DPR) is presently 13.46%.

Key Stories Impacting Revvity

Here are the key news stories impacting Revvity this week:

• Positive Sentiment: Zacks Research raised Revvity’s near-term and FY2026 estimates (Q2 2026 to $1.31, Q3 2026 to $1.34 and FY2026 to $5.36), reflecting stronger-than-expected momentum and aligning with company guidance; higher FY2026 estimates support revenue/earnings beat narratives. MarketBeat: Revvity estimates
• Positive Sentiment: Investors are also responding to coverage of Revvity’s strong Q4 beat and upbeat 2026 outlook — the company reported quarterly EPS and revenue above consensus and provided FY2026 guidance that analysts view as constructive for near-term growth. How Investors May Respond To Revvity Strong Q4 Beat
• Neutral Sentiment: Third‑party comparisons and sector context (e.g., Progyny vs. Revvity) are circulating but are unlikely to materially move the stock absent new company-specific guidance or results. Financial Comparison: Progyny vs. Revvity
• Negative Sentiment: Zacks trimmed several 2027 estimates (Q1 2026 cut to $1.03, Q2/Q3 2027 cuts and FY2027 reduced to $5.90 from $5.97), which temper longer‑term growth expectations and could cap multiple expansion if analysts continue to lower longer-dated forecasts. MarketBeat: Revvity estimates

About Revvity

Revvity, Inc is a global provider of technology-enabled solutions for the life sciences, diagnostics and applied markets. The company develops and supplies a range of products and services, including reagents and consumables, laboratory instruments, workflow automation, software analytics and technical support. Its portfolio supports applications in drug discovery, genomics, cell biology research, environmental and food safety testing, industrial quality control and clinical diagnostics.

Tracing its heritage to Perkin-Elmer, founded in 1937, Revvity began trading on the New York Stock Exchange under the ticker symbol RVTY in January 2024 following a corporate rebranding.